ONECUT2 and neoplasm: Surprisingly, the non-targeted CL/pshOC-2 lipoplexes (i.v.)which showed poor transfection efficiency in vitro, also inhibited the expression of OC-2 (22.9%) and tumor growth (51.7% in tumor weight and 53.8% in volume) in vivo, and its antitumor effect was only marginally inferior to the targeted cRGD-CL/pshOC-2 lipoplexes (i.v.).